About Us | ScientistIMRA IMARA Inc.
Upcoming Catalysts
| Drug | Stage | Catalyst Date |
|---|---|---|
|
IMR-687 (Ardent)
Sickle cell disease (SCD)
|
Phase 2b
Phase 2b
|
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
|
|
IMR-687 (Forte)
b-thalassemia
|
Phase 2b
Phase 2b
|
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
|
Drug Pipeline
| Drug | Stage | Notes |
|---|---|---|
|
IMR-687
Sickle cell disease
|
Phase 2a
Phase 2a
|
Phase 2a data to be presented at EHA meeting June 11, 2021 - well-tolerated safety profile. 40% lower mean annualized VOC rate versus placebo.
|
Latest News
-
View Full Article Hide Full Article
BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, August 6, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and review recent business highlights.
A live webcast will be available under "Events and Presentations" in the Investors section of the company's website. The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 6499377. A replay of the webcast will be archived on the Imara website following the presentation.
About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
[email protected]Investor Contact:
Michael Gray
617-835-4061
[email protected]
-
View Full Article Hide Full Article
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the "Company") (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced the pricing of its previously announced underwritten public offering of shares of its common stock at a public offering price of $6.00 per share, for gross proceeds of $50 million, before underwriting discounts and commissions and offering expenses payable by the Company. The offering is expected to close on July 16, 2021, subject to customary closing conditions. All shares are being offered by the Company. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase up to $7.5 million of additional shares of its common stock at the public offering price, less underwriting discounts and commissions.
Morgan Stanley, SVB Leerink and Cantor are acting as joint book-running managers for the offering.
The shares are being offered by the Company pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (the "SEC") on April 1, 2021 and declared effective on April 8, 2021. This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
The securities referred to in this release are to be offered only by means of the prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to, and describing the terms of, the offering has been filed with the SEC and is available on the SEC's web site at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering can be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; or SVB Leerink LLC, One Federal Street, 37th Floor, Boston, Massachusetts, 02110, Attention: Syndicate Department, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected].
About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types.Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected closing of the public offering. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the "Risk Factors" section of the Company's most recent Quarterly Report on Form 10-Q, which is on file with the SEC and in other filings that the Company makes with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
[email protected]Investor Contact:
Michael Gray
617-835-4061
[email protected] -
View Full Article Hide Full Article
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the "Company") (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that it has commenced a proposed underwritten public offering of $50 million of shares of its common stock. All of the shares are being offered by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock.
Morgan Stanley, SVB Leerink and Cantor are acting as joint book-running managers for the proposed offering.
The proposed offering of these securities is being made pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (the "SEC") on April 1, 2021 and declared effective on April 8, 2021. A preliminary prospectus supplement relating to, and describing the terms of, the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov. This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
The securities referred to in this release are to be offered only by means of a prospectus and prospectus supplement that form a part of the registration statement. Copies of the preliminary prospectus relating to the offering can be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; or SVB Leerink LLC, One Federal Street, 37th Floor, Boston, Massachusetts, 02110, Attention: Syndicate Department, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected].
About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the proposed offering and its terms. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the "Risk Factors" section of the Company's most recent Quarterly Report on Form 10-Q, which is on file with the SEC and in other filings that the Company makes with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
[email protected]Investor Contact:
Michael Gray
617-835-4061
[email protected] -
View Full Article Hide Full Article
BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the election of Laura A. Williams, M.D., MPH to its Board of Directors. Dr. Williams brings 25 years of early-to-late-stage drug development experience across multiple therapeutic areas, as well as expertise in patient advocacy to Imara.
"We're thrilled to welcome Dr. Williams to our Board," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "In addition to her significant experience leading clinical trials and guiding products through clinical development, she is a strong advocate for the patient community, making her an outstanding addition to our Board. Her integrated view across numerous important operating functions will greatly help our IMR-687 development efforts, as it continues to advance through the clinic for the treatment of sickle cell disease and beta-thalassemia."
Dr. Williams has served as Senior Vice President of Global Therapeutic Strategies and Patient Advocacy at Ardelyx since November 2020, where she is also a member of the Executive Leadership Team. In this role, she seeks to enhance the credibility of patient advocacy as a life science function and is also charged with developing the company's portfolio strategy, prioritizing the access of novel therapies to patients in areas of unmet need. Prior to Ardelyx, Dr. Williams was Senior Vice President and Head of Clinical Development and Biostatistics at AMAG Pharmaceuticals, where she was responsible for investigational-stage assets, on-market compounds and late-stage development activities. Previously, she was Vice President of Clinical Development at Myovant Sciences, overseeing early-stage clinical development and co-leading business development activities. Ahead of this role, Dr. Williams spent 18 years at Abbott/AbbVie managing clinical development programs across several therapeutic areas in multiple roles of increasing responsibility.
"I am excited to be working with the Imara team as the company continues to make progress towards its goal of treating patients suffering from hemoglobinopathies," added Dr. Williams. "Imara's work prioritizes both science and the patient voice, a strategy I've aligned with during my professional career in biotech and as a clinician treating patients."
Dr. Williams received a Bachelor of Science degree from Mississippi State University, a Doctor of Medicine degree from the University of Iowa, and a Master of Public Health degree in Epidemiology from the University of Washington, where she also completed a clinical fellowship in Infectious Diseases. She completed her Internal Medicine residency at the University of Michigan, where she also served as Chief Resident and Junior Faculty.
Concurrent with the election of Dr. Williams, Mette Kirstine Agger's term on the company's Board of Directors ended. Ms. Agger had served as a member of the company's Board since January 2016.
"I would like to thank Mette for her numerous contributions to Imara since joining the Board," added Ballal. "Mette has been a thoughtful partner to our Board and management team and her support and guidance have been invaluable as Imara has grown over these last five years."
About IMR-687
IMR-687 is a highly selective and potent small molecule inhibitor of PDE9. PDE9 uniquely degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule that plays a role in vascular biology. Lower levels of cGMP are often found in people with sickle cell disease and beta-thalassemia and are associated with impaired blood flow, increased inflammation, greater cell adhesion and reduced nitric oxide-mediated vasodilation.Blocking PDE9 acts to increase cGMP levels, which are associated with reactivation of fetal hemoglobin, or HbF, a natural hemoglobin produced during fetal development. Increased levels of HbF in red blood cells have been demonstrated to improve symptomology and lower disease burden in patients with sickle cell disease and patients with beta-thalassemia. IMR-687 is designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators, and other cell types.
About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.Cautionary Note Regarding Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the Company's plans, strategies and prospects. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the factors discussed in the "Risk Factors" section of the Company's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission and in other filings that the Company makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
[email protected]Investor Contact:
Michael Gray
617-835-4061
[email protected] -
View Full Article Hide Full Article
BOSTON, June 17, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the grant recipients of its second annual Real Impact community support initiative. This program, which includes grant funding to support nonprofit, community-based organizations (CBOs) serving patients and families impacted by sickle cell disease (SCD) and beta-thalassemia, awarded 30 grants to CBOs in 16 states totaling $150,000. The grant funding was increased by $25,000 from 2020, the program's inaugural year.
"We are proud of the positive effects the Real Impact program has had on the health and lives of patients, their families, and their local communities to date," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "Expanding the program for its second year reflects our continued commitment to foster innovative ideas and let local community organizations further accomplish their goals of supporting people affected by sickle cell disease and beta-thalassemia."
Grant applications were assessed based on metrics including clear identification of an unmet need, plan of execution, level of impact within the target community and proposed measures of success. Importantly, each grant committee consisted of external reviewers and decisions to fund applications were made independent of Imara's executive officers. Of the 30 awards, 10 of the selected programs focus on social drivers that can impact quality of life; 9 others support virtual programing and 11 will fund organizational capacity enhancements.
"Crescent Foundation is very appreciative to receive funding through the Imara Real Impact Grant program to help support our One Gene, One Life program," said Kyle Smith, CEO and Co-Founder at the Crescent Foundation. "The One Gene, One Life program focuses on highlighting the needs of the sickle cell disease community to future medical practitioners. We're eager to continue this work and shed biases and lessen stigmas associated with sickle cell disease."
Real Impact grant recipients include:
Social Determinants of Health (Include COVID-19 Relief) Grants
- Carol's Promise Sickle Cell Foundation
- MTS Sickle Cell Foundation, Inc.
- Sickle Cell Anemia Foundation of Oregon
- Sickle Cell Disease AA MI
- Sickle Cell Disease Association of America
- Sickle Cell Disease Association of America Inc: Miami-Dade County Chapter, Inc.
- Sickle Cell Texas Marc Thomas Foundation
- Sickle Cell Warriors, Inc.
- Sickled Not Broken Foundation of NV, Inc.
- Supporters of Families with Sickle Cell Disease, Inc.
Virtual Support Program Grants
- Bridges Pointe, Inc.
- Cayenne Wellness Center | Sickle Cell Education, Support, and Advocacy
- Children's Sickle Cell Foundation, Inc.
- Life and Family Foundation, VA
- Piedmont Health Services and Sickle Cell Agency
- Sickle Cell Association
- Sickle Cell Disease Foundation
- Sickle Cell Foundation of Georgia, Inc.
- South Central PA Sickle Cell Council
Capacity Support Grants
- Advancing Sickle Cell Advocacy Project, Inc.
- As One Foundation
- Association for the Prevention of Sickle Cell Anemia, Inc.
- Cooley's Anemia Foundation Inc.
- Crescent Foundation
- Dreamsickle Kids Foundation, Inc.
- Hina Patel Foundation
- Metropolitan Seattle Sickle Cell Task Force
- Sickle Cell Anemia Awareness San Francisco
- Sickle Cell Consortium
- The Sickle Cell Association of New Jersey
"Every day, the Imara team strives to serve those affected by sickle cell disease and beta-thalassemia as well as their care networks," said Jennifer Fields, Director of Advocacy. "Community-based organizations have a first-hand understanding of patient and family needs at a local level, and we appreciate the opportunity to directly support the many important and innovative ways they serve their constituencies."
About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.Cautionary Note Regarding Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the Company's future advocacy programs. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the factors discussed in the "Risk Factors" section of the Company's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission and in other filings that the Company makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
[email protected]Investor Contact:
Michael Gray
617-835-4061
[email protected]